Skip to main content
PlainMeds

What the label lists and what reports show

Cangrelor side effects

Cangrelor's FDA label: “The most common adverse reaction is bleeding.” FAERS holds 399 reports naming it through July 30, 2026; the reaction reported most often, leaving out the conditions it is used for, product-use terms and outcomes, is vascular stent thrombosis (32 reports).

  • Generic listed

Check it at the source: the cangrelor FDA label on DailyMed (effective October 21, 2025, Chiesi USA, Inc.); the FDA FAERS public dashboard.

What does the label list?

From the label: adverse reactions

The most common adverse reaction is bleeding.

From the label: adverse reactions, continued

The following adverse reactions are also discussed elsewhere in the labeling: Bleeding [see Warnings and Precautions ( 5.1 )] The most common adverse reaction is bleeding. ( 5.1 , 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Chiesi USA, Inc. at 1-888-661-9260 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reactions rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. The safety of KENGREAL has been evaluated in 13,301 subjects in controlled trials, in whom, 5,529 were in the CHAMPION PHOENIX trial. Bleeding There was a greater incidence of bleeding with KENGREAL than with clopidogrel. No baseline demographic factor altered the relative risk of bleeding with KENGREAL (see Table 1 and Figure 1). …

Source: FDA drug label, Chiesi USA, Inc., effective October 21, 2025 (SPL set 88b434fa-8891-4fd5-9d86-7ea64667c08f), via openFDA; the full label on DailyMed

What do FAERS reports show?

399 reports list cangrelor among the medicines taken, each a report of something that happened, not proof the medicine caused it; 84 are coded as a death and 81 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is. Of the 16 reactions below, 2 are named by the same term (in US spelling) in the label's adverse reactions, warnings or patient leaflet; a reaction the label does not name may still be there under another word, and a report does not show that the medicine caused it.

The 25 most reported reactions

  • Off Label Use (a use or a product term, not a reaction)160
  • Vascular Stent Thrombosis32
  • Drug Ineffective (a use or a product term, not a reaction)29
  • Haemorrhage (named in the label)26
  • Death (an outcome recorded in the report)22
  • No Adverse Event (a use or a product term, not a reaction)20
  • Cardiac Arrest18
  • Inappropriate Schedule Of Product Administration (a use or a product term, not a reaction)18
  • Cardiogenic Shock15
  • Gastrointestinal Haemorrhage14
  • Dyspnoea (named in the label)12
  • Labelled Drug-Drug Interaction Medication Error (a use or a product term, not a reaction)12
  • Intentional Product Use Issue (a use or a product term, not a reaction)11
  • Cerebral Haemorrhage10
  • Haemorrhage Intracranial10
  • Cardiac Failure9
  • Drug Ineffective For Unapproved Indication (a use or a product term, not a reaction)9
  • Vascular Access Site Haemorrhage9
  • Eosinophilia8
  • Incorrect Drug Administration Rate8
  • Pulmonary Haemorrhage8
  • Thrombosis (a use or a product term, not a reaction)8
  • Cerebrovascular Accident7
  • Hypotension7
  • Mixed Liver Injury7

Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026; reactions as MedDRA preferred terms

What next?

Cangrelor: the full record
label, generics, price, shortages, recalls
Side effects hub
the most reported medicines and reactions